• News
  • BioTech

Ligand revises 4Q, 2013 financial forecast upward

Ligand Pharmaceuticals Inc. (Nasdaq: LGND) is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol material.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals Inc.

Company Website

10275 Science Center Drive
San Diego, CA 92121

Subscribe Today!